Evidence map›Paper›PMID 32130567›Full record

ArticleMagma (New York, N.Y.)2020

Treatment margins in radiotherapy for liver tumors visualized as T2*-hypointense areas on SPIO-enhanced MRI at 9.4 T.

Toshihiro Furuta, Masayuki Yamaguchi, Manabu Minami, Osamu Abe, Hirofumi Fujii

Abstract read
PubMed Publisher
In one paragraph

Article in Magma (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Toshihiro FurutaDivision of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwanoha 6-5-1, Kashiwa, Chiba, 277-8577, Japan. tfuruta-tky@umin.ac.jp.
Masayuki YamaguchiDivision of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwanoha 6-5-1, Kashiwa, Chiba, 277-8577, Japan.
Manabu MinamiDepartment of Radiology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tennodai 1-1-1, Tsukuba, Ibaraki, 305-8577, Japan.
Osamu AbeDepartment of Radiology, Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655, Japan.
Hirofumi FujiiDivision of Functional Imaging, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Kashiwanoha 6-5-1, Kashiwa, Chiba, 277-8577, Japan.

Funding

Japan Radiological Society KJ-20Japan Society for the Promotion of Science 16K10332
6 · The paper itself

Abstract

objectiveTo investigate whether a SPIO-labeling technique could enable MR visualization of the treatment margin after X-irradiation at a single dose of 30 Gy. MATERIALS AND

methodsFifteen rats bearing N1-S1 hepatoma in either the left (group 1) or right (group 2) liver lobe were examined. Four hours after systemic SPIO administration, the left lobe was selectively irradiated at 30 Gy. Liver T2* maps were acquired 7 days later using a 9.4 T scanner. The livers were excised and examined histologically.

resultsThe irradiated area showed T2*-weighted hypointensity with significantly shorter T2* values than those in the non-irradiated area (p < 0.001). Tumors in group 1 completely disappeared, whereas tumors in group 2 had grown outside the T2*-weighted hypointensity by up to ~ 2.3 times that at baseline. Group 1 showed significantly higher probability of tumor regression than group 2 (p = 0.048). Histologically, iron deposition was heavier in irradiated areas than in non-irradiated areas. DISCUSSION: Even at a single dose of 30 Gy, which is a slightly higher dose than can be used clinically in stereotactic body radiotherapy, MR visualization of the treatment margin was achieved, because tumors showed significant growth outside the T2*-hypointense areas. In contrast, tumors disappeared inside the T2*-hypointense areas.

Indexed as

Liver NeoplasmsMagnetite NanoparticlesAnimalsContrast MediaDextransFerric CompoundsLiverMagnetic Resonance ImagingRatsContrast MediaDextransFerric Compoundsferric oxideMagnetite NanoparticlesLiver tumorMRIRadiationSuperparamagnetic iron oxide

Identifiers

PMID32130567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.